Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2 and AE37 Peptide Vaccines in Breast Cancer
NCT00524277Phase 2Completed
- Sponsor
- Brooke Army Medical Center
- Start
- Jan 2007
- Primary completion
- Dec 2014
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of GP2 peptide, AE37 in breast cancer, sponsored by Brooke Army Medical Center. Started Jan 2007; status: completed.
02
Drugs
GP2 peptideAE37
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00524277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00524277.